Trial reportMedical oncology (Northwood, London, England)2014
Serum human kallikrein 7 represents a new marker for cervical cancer.
Trial report in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multidimensional outlook on the pathophysiology of cervical cancer invasion and metastasis.Molecular and cellular biochemistry · 2023Review
- Serum Actinin-4 Levels as a Potential Diagnostic and Prognostic Marker in Cervical Cancer.Disease markers · 2020Article
- Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.Clinical immunology (Orlando, Fla.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study was aimed to investigate the diagnostic and prognostic performance of serum human tissue kallikrein 7 (KLK7) in cervical cancer. The study comprised of 78 patients with cervical cancer, 36 patients with benign cervical diseases, and 50 healthy controls. Serum KLK7 levels were determined using ELISA method. Receiver operating characteristic curve was performed to assess the diagnostic performance of serum KLK7. Survival curves by the Kaplan-Meier method were plotted to display overall survival distributions. Univariable and multivariable Cox regression analysis were performed to assess independent prognostic factors for overall survival in cervical cancer. Serum KLK7 levels in cervical cancer patients were 3.13±1.99 μg/ml, significantly higher than the values obtained from patients with benign cervical disease (1.40±1.14 μg/ml; P<0.001) and healthy controls (1.27±0.73 μg/ml; P<0.001), respectively. The sensitivity, specificity, positive and negative predictive values of serum KLK7 for cervical cancer were 75.6, 80.2, 77.6, and 78.4%, respectively. Serum KLK7 levels in patients with cervical cancer were significantly correlated with FIGO stage, lymph node metastasis, and stromal invasion. When analyzed with a survival curve, high serum KLK7 level was correlated with poor prognosis. Our findings suggest that serum KLK7 may be a valuable diagnostic biomarker for cervical cancer, and may help to determine the individual prognosis of these patients.
Indexed as
Identifiers
25182706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.